Physician profile
Dean Heller
NPI 1093815508
$7,725.70
in general payments reported to CMS, 2019-2025
28 companies · $479 in 2025
The $479 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,930 · 2020: $707 · 2021: $1,857 · 2022: $699 · 2023: $1,063 · 2024: $990 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,512 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,511.93 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $1,582.74 | 2019-2021 | |
| Abbott Laboratories | $1,036.60 | 2019-2025 | Aveir, Gallant, Jot Dx |
| Amgen INC. | $1,024.22 | 2019-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $716.95 | 2019-2024 | |
| Arbor Pharmaceuticals, INC. | $409.78 | 2019-2020 | |
| Esperion Therapeutics, INC. | $370.04 | 2020-2023 | Nexletol |
| Janssen Pharmaceuticals, INC | $314.05 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $312.56 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $240.23 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $231.94 | 2019-2024 | Farxiga |
| Azurity Pharmaceuticals, INC. | $226.57 | 2023-2025 | Edarbi, Edarbi, Edarbyclor |
| E.R. Squibb & Sons, L.L.C. | $199.37 | 2019-2025 | Eliquis |
| Boston Scientific Corporation | $189.81 | 2023 | Watchman Flx |
| Impulse Dynamics (USA) INC. | $177.41 | 2022 | |
| Merck Sharp & Dohme LLC | $173.80 | 2021-2025 | Verquvo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $115.50 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $70.39 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $63.32 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $48.96 | 2024 | |
| Philips North America LLC | $47.35 | 2023 | |
| Terumo Medical Corporation | $29.86 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $26.48 | 2024 | Arcalyst |
| Vifor Pharma, INC. | $23.60 | 2019 | |
| Pfizer INC. | $21.20 | 2021 | |
| Lilly USA, LLC | $20.91 | 2025 | Mounjaro, Zepbound |
| Biocompatibles, INC. | $20.46 | 2019 | |
| Amryt Pharma Holdings LTD | $18.21 | 2021 | |
| Zoll Circulation INC | $13.39 | 2023 | Therox Ds2 Console, Downstream Cartridge, Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Heller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.